KB-1451

JNJ64407564-CD3-hIgG1

45716

Home » Antibodies » JNJ64407564-CD3-hIgG1

Background of JNJ64407564-CD3-hIgG1

Talquetamab, marketed under the brand name Talvey, is a humanized monoclonal antibody employed in the treatment of multiple myeloma. Talquetamab antibody targets two distinct entities: human CD3, a surface antigen present on T cells, and human G-protein coupled receptor family C group 5 member D (GPRC5D), identified as a tumor-associated antigen with promising antineoplastic properties. JNJ64407564-CD3-hIgG1 is a monoclonal antibody that binds to the CD3 protein.

Specifications

Catalog Number	KB-1451
Antibody Name	JNJ64407564-CD3-hIgG1
Isotype	Human IgG1,lambda
Target	CD3E&CD3D
Species Reactivity	Human
Host Cell Line	EXPI CHO
Purification Method	Affinity purified
Concentration	>2 mg/mL
Formulation	50 mM sodium citrate,150mM NaCl,pH5.5
Purity	>95% by SDS-PAGE and SEC-HPLC
Validation	ELISA
Endotoxin Level	<0.2 EU/mg as determined by the LAL method
Sterility	0.2μm filtered
Storage	It is recommended that the protein should be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Stability	Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.

Characterization

Application

References

Verkleij CPM, Broekmans MEC, van Duin M, Frerichs KA, Kuiper R, de Jonge AV, Kaiser M, Morgan G, Axel A, Boominathan R, Sendecki J, Wong A, Verona RI, Sonneveld P, Zweegman S, Adams HC, Mutis T, van de Donk NWCJ: Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma. Blood Adv. 2021 Apr 27;5(8):2196-2215.
Pillarisetti K, Edavettal S, Mendonca M, Li Y, Tornetta M, Babich A, Majewski N, Husovsky M, Reeves D, Walsh E, Chin D, Luistro L, Joseph J, Chu G, Packman K, Shetty S, Elsayed Y, Attar R, Gaudet F: A T-cell-redirecting bispecific G-protein-coupled receptor class 5 member D x CD3 antibody to treat multiple myeloma. Blood. 2020 Apr 9;135(15):1232-1243.